Phase 2 Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were born male or female.
- People who are between 18 and 75 years old (inclusive) at the time of signing the consent form.
- People whose blood sugar control measure (called HbA1c) falls within a specific range (7.0–10.0%) as tested by the trial's central laboratory during the screening process.
- People who are willing to aim for a high level of weight loss — more than 25% of their starting body weight.
Who may not be able to join:
- People who have taken any medication for diabetes or obesity in the 90 days before screening (with some exceptions: short-term insulin use for up to 14 days in a row, or past insulin use during pregnancy-related diabetes, may be allowed — confirm with trial site).
- People who have diabetic eye disease (affecting the retina or a part of the eye called the macula) that is not well controlled or may be unstable. An eye examination using pupil-dilating drops is required as part of screening, unless a specific type of non-dilating camera is used (confirm with trial site).
- People who have a condition where they do not notice the warning signs of low blood sugar, as determined by the investigating doctor using a standard questionnaire.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in glycated haemoglobin (HbA1c) (week 16); Change in HbA1c (week 28); Change in HbA1c (week 40)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.